Icosavax, Inc. (ICVX): Price and Financial Metrics


Icosavax, Inc. (ICVX): $10.23

2.07 (+25.37%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ICVX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ICVX Stock Price Chart Interactive Chart >

Price chart for ICVX

ICVX Price/Volume Stats

Current price $10.23 52-week high $49.99
Prev. close $8.16 52-week low $4.00
Day low $8.02 Volume 256,287
Day high $10.67 Avg. volume 300,549
50-day MA $8.52 Dividend yield N/A
200-day MA $20.74 Market Cap 406.44M

Icosavax, Inc. (ICVX) Company Bio


Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-A12, an respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-121, a vaccine candidate with RSV target; IVX-241, a vaccine candidate with hMPV target; IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2^ target indication; and IVX-421, a variant RBD antigen with SARS-CoV-2^ target indication. The company was incorporated in 2017 and is headquartered in Seattle, Washington.


ICVX Latest News Stream


Event/Time News Detail
Loading, please wait...

ICVX Latest Social Stream


Loading social stream, please wait...

View Full ICVX Social Stream

Latest ICVX News From Around the Web

Below are the latest news stories about Icosavax Inc that investors may wish to consider to help them evaluate ICVX as an investment opportunity.

Pan-COVID-19 Vaccine Could Be a Solution to End the Pandemic; Jefferies Taps 2 Stocks to Benefit

The coronavirus pandemic is still making headlines; it’s presenting us with a stubborn problem, one that won’t go away and resists the normal weapons that modern medicine has brought against it. The result is a sense of fatalism, that we may as well just get used to corona. No one likes that idea. The medical researchers, especially, aren’t liking that, and they are working to bring new techniques to bear on the virus. Among the more promising is the ‘pan-COVID’ approach, the development of a va

Yahoo | January 20, 2022

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and Icosavax (ICVX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report) and Icosavax (ICVX – Research Report) with bullish sentiments. BioMarin Pharmaceutical (BMRN) In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $100.00. The company's shares closed last Friday at $84.25. According to TipRanks.

Catie Powers on TipRanks | January 10, 2022

Icosavax outlines anticipated milestones for 2022

No summary available.

Seeking Alpha | January 7, 2022

Icosavax Provides Corporate Update and Anticipated Milestones for 2022

SEATTLE, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today provided a corporate update and shared anticipated milestones for 2022. Pipeline Updates: Exercised option for patent license for influenza vaccine from the University of Washington (UW) and U.S. Department of Human and Health Services (HHS). Icosavax has exercised its o

Yahoo | January 7, 2022

Icosavax Appoints Dr. John Shiver to Board of Directors

- Dr. Shiver has contributed to the licensure of 14 pharmaceutical addressing global infectious diseases -SEATTLE, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced the appointment of John Shiver, Ph.D., to its Board of Directors. Dr. Shiver has more than 30 years of experience in vaccine and pharmaceutical research an

Yahoo | January 5, 2022

Read More 'ICVX' Stories Here

ICVX Price Returns

1-mo 33.90%
3-mo -41.88%
6-mo -62.87%
1-year N/A
3-year N/A
5-year N/A
YTD -55.29%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.4725 seconds.